Inhibikase Therapeutics
IKT
31 hedge funds and large institutions have $163M invested in Inhibikase Therapeutics in 2024 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 7 increasing their positions, 0 reducing their positions, and 3 closing their positions.
14,452% more capital invested
Capital invested by funds: $1.12M → $163M (+$162M)
667% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 3
182% more funds holding
Funds holding: 11 → 31 (+20)
62.99% more ownership
Funds ownership: 11.53% → 74.53% (+63%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCV
Sands Capital Ventures
Arlington,
Virginia
|
+$27.3M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$15.8M |
| 3 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$15.3M |
| 4 |
CC
Commodore Capital
New York
|
+$14.8M |
| 5 |
PA
Perceptive Advisors
New York
|
+$14.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$814K |
| 2 |
Renaissance Technologies
New York
|
-$25.9K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.27K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
JFG
26
Jefferies Financial Group
New York
| $48.1K | +$36.9K | +14,800 | New |
|
27
Stifel Financial
St. Louis,
Missouri
| $42.7K | +$32.8K | +13,129 | New |
|
28
Morgan Stanley
New York
| $23.7K | +$14K | +5,629 | +338% |
|
29
Bank of America
Charlotte,
North Carolina
| $14.7K | +$11.1K | +4,456 | +8,408% |
|
30
Wells Fargo
San Francisco,
California
| $543 | – | – | – |
|
|
SAM
31
Synergy Asset Management
Vancouver,
Washington
| $65 | +$125 | +50 | New |
|
|
AC
32
Armistice Capital
New York
| – | -$814K | -626,500 | Closed |
|
|
33
Renaissance Technologies
New York
| – | -$25.9K | -19,922 | Closed |
|
|
TRCT
34
Tower Research Capital (TRC)
New York
| – | -$5.27K | -4,057 | Closed |
|
IKT Hedge Fund Activity: Q4 2024 in Review
31 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q4 2024, worth a combined $163M — up 14,452% from $1.12M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new IKT positions and 3 closed out — a net gain of 20 holders — while 7 added to existing stakes and 0 trimmed.
The largest buyer was Sands Capital Ventures, opening a new position worth an estimated $27.3M. The largest seller was Armistice Capital, exiting entirely with an estimated $814K sold.
- 31 institutional investors held Inhibikase Therapeutics (IKT) as of Q4 2024, up from 11 in Q3 2024.
- Funds reported $163M of Inhibikase Therapeutics stock for Q4 2024, up 14,452% quarter-over-quarter.
- 23 funds opened new Inhibikase Therapeutics positions in Q4 2024 and 3 closed out, a net change of +20 holders.
- The largest Inhibikase Therapeutics buyer in Q4 2024 was Sands Capital Ventures, an estimated $27.3M added.
- The largest Inhibikase Therapeutics seller in Q4 2024 was Armistice Capital, an estimated $814K sold.
Based on aggregated 13F filings for Q4 2024.